Berberine for Fatty Liver: Evidence and UK Advice

Berberine and fatty liver disease is a topic attracting growing interest, particularly as metabolic dysfunction-associated steatotic liver disease (MASLD) becomes increasingly common in the UK. Berberine is a plant-derived compound sold as a food supplement, and early research suggests it may help reduce liver fat and improve related metabolic markers. However, it is not a licensed medicine and is not recommended by NICE or the NHS as a treatment. This article explains how berberine works on the liver, what the clinical evidence shows, and what you should know before considering it.

What is fatty liver disease and how common is it in the UK?

Fatty liver disease, particularly MASLD (formerly NAFLD), is one of the most prevalent chronic liver conditions in the UK, closely linked to obesity, type 2 diabetes and insulin resistance, and often undiagnosed due to its asymptomatic early stages.

Fatty liver disease is one of the most prevalent chronic liver conditions in the UK, with estimates suggesting it affects a substantial proportion of adults, though figures vary across studies and the condition is frequently undiagnosed. The condition is broadly divided into two categories: alcohol-related liver disease (ARLD), in which simple steatosis (fatty change) is an early stage alongside more advanced forms such as alcoholic hepatitis and cirrhosis; and metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). UK patient resources, including NHS and NICE materials, may still use the term NAFLD, so the two terms are used interchangeably in this context. MASLD is the more common form and is closely linked to obesity, type 2 diabetes, high blood pressure and raised cholesterol.^[1][2]

In MASLD, excess fat accumulates within liver cells (hepatocytes), impairing normal liver function. In many people the condition remains stable, but in a proportion it can progress through stages of increasing inflammation (metabolic dysfunction-associated steatohepatitis, or MASH) to fibrosis, cirrhosis and, in some cases, liver failure or hepatocellular carcinoma. NICE guidance (NG49) highlights the importance of early identification and lifestyle intervention, and recommends that people with MASLD/NAFLD in primary care have their risk of advanced fibrosis assessed using a scoring tool such as the FIB-4 index or the NAFLD Fibrosis Score. Where the result is indeterminate or suggests higher risk, an enhanced liver fibrosis (ELF) test may be used, and referral to hepatology is recommended if advanced fibrosis is suspected. Specific score thresholds and age-adjusted cut-offs should be confirmed against the current NICE NG49 guidance and local integrated care board (ICB) pathways.

Risk factors for MASLD include a body mass index (BMI) above 25 kg/m², central adiposity, insulin resistance and a sedentary lifestyle. Because the condition is often asymptomatic in its early stages, many people are diagnosed incidentally through abnormal liver function tests or imaging performed for another reason. Awareness of modifiable risk factors is therefore central to prevention and management.

If you develop new or worsening symptoms that may suggest liver disease progressing, seek prompt medical attention. Symptoms warranting same-day assessment include new jaundice (yellowing of the skin or eyes), persistent or severe abdominal pain, or marked abdominal swelling. Symptoms such as confusion or drowsiness, vomiting blood or passing black tarry stools, or severe unexplained bleeding require emergency assessment: call 999 or go to your nearest A&E department.

How does berberine work on the liver?

Berberine primarily activates AMPK, reducing hepatic fat synthesis and promoting fat oxidation, while also lowering inflammation, improving insulin sensitivity and modulating gut microbiome composition.

Berberine appears to act on the liver primarily by activating an enzyme called AMP-activated protein kinase (AMPK), which plays a central role in regulating cellular energy balance and lipid metabolism. AMPK activation reduces the synthesis of fatty acids and triglycerides within the liver, while simultaneously promoting fat oxidation, which together may help to reduce hepatic fat accumulation.

Beyond lipid metabolism, berberine has been shown in laboratory and animal studies to influence several other pathways relevant to fatty liver disease. These include reducing oxidative stress and inflammatory signalling (notably through inhibition of nuclear factor kappa B, or NF-kB), improving insulin sensitivity, and modulating the composition of the gut microbiome.^[8] Dysbiosis of the gut microbiome is increasingly recognised as a contributor to MASLD, and berberine's effects on gut bacteria may represent an additional mechanism of benefit.

Berberine also appears to reduce the expression of genes involved in lipogenesis (the creation of new fat) in the liver, including sterol regulatory element-binding protein 1c (SREBP-1c). It may additionally lower blood glucose and improve lipid profiles, both of which are relevant to the metabolic drivers of MASLD.

Berberine has very low oral bioavailability, which may limit the extent to which laboratory findings translate to clinical benefit in humans.^[9][10] It also inhibits certain drug transporter proteins, including P-glycoprotein (P-gp), in addition to cytochrome P450 enzymes, which is relevant to its potential for interactions with prescribed medicines (discussed further below).^[11][12]

It is important to note that most mechanistic evidence comes from in vitro (cell-based) and animal studies, and the degree to which these pathways translate directly to clinical benefit in humans requires further investigation.

What does the evidence say about berberine for fatty liver?

Small trials and meta-analyses show berberine modestly reduces liver enzymes and liver fat on ultrasound, but evidence on histological improvement, fibrosis regression and long-term safety remains insufficient.

Clinical evidence suggests berberine may modestly improve markers of fatty liver disease in adults with MASLD, though the overall evidence base remains limited in scale and quality. Several small randomised controlled trials and meta-analyses have reported reductions in liver enzymes (alanine aminotransferase and aspartate aminotransferase), improvements in liver fat content measured by ultrasound, and favourable changes in fasting blood glucose, triglycerides and total cholesterol following berberine supplementation.

A meta-analysis published in Frontiers in Pharmacology (2020) pooled data from multiple trials and found statistically significant reductions in liver enzyme levels and lipid parameters in participants taking berberine compared with placebo or lifestyle intervention alone.^[16] However, the trials included were generally small (often fewer than 100 participants), of short duration (typically 12 to 24 weeks), and varied in dose and formulation, making it difficult to draw firm conclusions.^[16] Ultrasound-based measures of liver fat can also be operator-dependent and are less precise than histological assessment. Importantly, evidence on histological improvement (such as reduction in liver inflammation or fibrosis on biopsy), fibrosis regression, long-term clinical outcomes and long-term safety is currently lacking. Readers seeking the most up-to-date pooled evidence should check for systematic reviews published after 2020, as the field continues to evolve.

Berberine is not a licensed medicine in the UK and is not recommended by NICE or the NHS as a treatment for MASLD. Current NICE guidance (NG49) for MASLD centres on lifestyle modification, including weight loss, increased physical activity and dietary change, alongside management of associated metabolic conditions.^[1][2] Berberine should therefore be considered a supplement under investigation rather than an established therapy. People with known liver disease should consult their GP before starting any supplement, as interactions with prescribed medicines are possible.

How should you take berberine and what dose is typically used?

Research doses typically range from 500 mg to 1,500 mg daily, divided across two or three doses taken with food, but no official UK dosing guidance exists and interactions with prescribed medicines are a significant concern.

Berberine is not a licensed medicine in the UK, and no official dosing guidance has been issued by the MHRA, NICE or the NHS. The doses used in clinical research have typically ranged from 500 mg to 1,500 mg per day, most commonly divided into two or three doses.^[16] Dividing the daily dose and taking it alongside food appears to reduce gastrointestinal side effects, though whether this meaningfully improves absorption in humans is less clearly established. Because berberine is sold as a food supplement rather than a regulated medicine, formulations and bioavailability vary considerably between products. Do not exceed the dose stated on the product label.

Common side effects reported in trials include gastrointestinal symptoms such as nausea, diarrhoea, constipation and abdominal discomfort, particularly at higher doses. These effects are generally mild and often improve with dose reduction or by taking berberine alongside food.

More serious concerns include potential interactions with prescribed medicines. Berberine can inhibit cytochrome P450 enzymes (particularly CYP3A4 and CYP2D6) and P-glycoprotein (P-gp), which may affect the metabolism and transport of a range of drugs. UK-relevant examples of medicines that may be affected include statins such as simvastatin and atorvastatin, direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban, calcineurin inhibitors used in transplant medicine such as ciclosporin and tacrolimus, and certain antidiabetic agents. If you take any of these or other prescribed medicines, speak to your GP or pharmacist before starting berberine. People taking insulin or sulfonylureas (such as gliclazide) should be aware of a potential increased risk of hypoglycaemia (low blood sugar) when combined with berberine, and should seek clinical advice before use.

People who are pregnant or breastfeeding should avoid berberine, as safety in these groups has not been established. Those with existing liver or kidney conditions, or who are taking prescribed medication, should speak to their GP before starting berberine. Avoid combining berberine with other supplements that may affect the liver.

If you experience new or worsening symptoms such as jaundice or persistent abdominal pain while taking any supplement, contact your GP promptly for same-day assessment. Symptoms such as confusion, vomiting blood, passing black tarry stools or severe unexplained bleeding require emergency care: call 999 or go to A&E. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Berberine is not a substitute for evidence-based lifestyle changes, which remain the cornerstone of MASLD management.

Frequently Asked Questions